<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATGAM- equine thymocyte immune globulin injection, solution </strong><br>Pharmacia and Upjohn Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ATGAM safely and effectively. See full prescribing information for ATGAM.<br><br>ATGAM<span class="Sup">®</span> (lymphocyte immune globulin, anti-thymocyte globulin [equine]) sterile solution for intravenous use only<br>Initial U.S. Approval: 1981</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLAXIS</span></span></h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold">.</span>
</h1>
<p class="Highlighta"><span class="Bold">Antithymocyte globulins can cause <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> when injected intravenously. Although ATGAM is processed to reduce the level of antibodies that will react to non-T cells, physicians should be prepared for the potential risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and monitor patients for signs and symptoms during infusion.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="85%">
<col align="right" valign="top" width="15%">
<tbody class="Headless">
<tr>
<td align="left">Contraindications (<a href="#S4">4</a>)</td>
<td align="right">5/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#S5.1">5.1</a>)</td>
<td align="right">5/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Immunizations (<a href="#S5.3">5.3</a>)</td>
<td align="right">5/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Hepatic and Renal Function Tests (<a href="#S5.4">5.4</a>)</td>
<td align="right">5/2014</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLAXIS</span></span></h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold">.</span>
</h1>
<p class="Highlighta"><span class="Bold">Antithymocyte globulins can cause <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> when injected intravenously. Although ATGAM is processed to reduce the level of antibodies that will react to non-T cells, physicians should be prepared for the potential risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and monitor patients for signs and symptoms during infusion.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ATGAM is an <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> indicated for: </p>
<ul class="Disc">
<li> Renal <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>. (<a href="#S1.1">1.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span> (moderate to severe) in patients unsuitable for bone marrow transplantation. (<a href="#S1.2">1.2</a>)</li>
<li>
<span class="Bold">Limitations of Use:</span> The usefulness of ATGAM has not been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> who are suitable candidates for bone marrow transplantation or in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> secondary to neoplastic disease, storage disease, <span class="product-label-link" type="condition" conceptid="133169" conceptname="Myelofibrosis">myelofibrosis</span>, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation. (<a href="#S1.2">1.2</a>)</li>
</ul>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Intravenous use only.</span> </p>
<table width="100%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Indication</th>
<th class="Rrule" align="left">Dosage</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Renal <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span></td>
<td class="Rrule" align="left">10 to 15 mg/kg daily intravenously for 14 days; additional alternate-day therapy up to a total of 21 doses may be given. (<a href="#S2.1">2.1</a>)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span></td>
<td class="Rrule" align="left">10 to 20 mg/kg daily intravenously for 8 to 14 days; additional alternate-day therapy up to a total of 21 doses may be given. (<a href="#S2.1">2.1</a>)</td>
</tr>
</tbody>
</table>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>ATGAM 50 mg/mL concentrate for solution for infusion. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Systemic reaction (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) during prior administration of ATGAM or any other equine gamma globulin preparation. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Discontinue ATGAM if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occurs. (<a href="#S5.1">5.1</a>)</li>
<li> Serious immune-mediated reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported. To identify those at greatest risk, skin testing before treatment is strongly recommended. (<a href="#S5.1">5.1</a>)</li>
<li> Monitor patients for concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including cytomegalovirus. (<a href="#S5.2">5.2</a>) </li>
<li> Do not administer live vaccines to patients about to receive, receiving, or after treatment with ATGAM due to a potential of uncontrolled viral replication in the immunosuppressed patient. (<a href="#S5.3">5.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common (&gt;10%) adverse reactions are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>. (<a href="#S6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Previously masked reactions to ATGAM may appear following reduced doses of immunosuppressants. (<a href="#S7">7</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li> Pregnancy: Use only if the potential benefit justifies the risk. (<a href="#S8.1">8.1</a>)</li>
<li>Nursing Mothers: Discontinue nursing when administering ATGAM. (<a href="#S8.3">8.3</a>)</li>
<li>Geriatric: Start dosing at the low end of the dosage range. (<a href="#S8.5">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div><div><div></div></div></div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLAXIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Renal Allograft Rejection</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Transmissible Infectious Agents</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Immunizations</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Hepatic and Renal Function Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Renal Allograft Rejection</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	<span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLAXIS</span></span></h1>
<p class="First"><span class="Bold">Antithymocyte globulins can cause <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> when injected intravenously. Although ATGAM is processed to reduce the level of antibodies that will react to non-T cells, physicians should be prepared for the potential risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and monitor patients for signs and symptoms during infusion.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Renal Allograft Rejection</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1.1"></a><p></p>
<p class="First"><span class="Italics">Renal <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span></span>: ATGAM is indicated for the management of allograft rejection in renal transplant patients; when administered with conventional therapy at the time of rejection ATGAM increases the frequency of resolution of the acute rejection episode <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></h2>
<p class="First">ATGAM is indicated for the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> in patients unsuitable for bone marrow transplantation <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>The usefulness of ATGAM has not been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> who are suitable candidates for bone marrow transplantation or in patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> secondary to neoplastic disease, storage disease, <span class="product-label-link" type="condition" conceptid="133169" conceptname="Myelofibrosis">myelofibrosis</span>, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">ATGAM is intended for intravenous use only.</p>
<p>ATGAM is used with concomitant immunosuppressants. During repeat courses of ATGAM, observe patients for signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dose</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Renal Allograft Recipients</span></p>
<ul class="Disc"><li>
<span class="Italics">Renal <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>: </span>The recommended dose is 10 to 15 mg/kg daily intravenously for 14 days. Additional alternate-day therapy up to a total of 21 doses may be given.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span> (Moderate to Severe)</span></p>
<p>The recommended dose is 10 to 20 mg/kg daily intravenously for 8 to 14 days. Additional alternate-day therapy up to a total of 21 doses may be given. Because <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> can be associated with the administration of ATGAM, patients receiving it for the treatment of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> may need <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> platelet transfusions to maintain platelets at clinically acceptable levels.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2.1"></a><p></p>
<p class="First"><span class="Italics">Geriatric population (≥65 years of age)</span></p>
<p>Select the dose for an elderly patient with caution, starting at the low end of the dosage range <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Preparation and Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Preparation of Solution</span></p>
<ul class="Disc">
<li>Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. However, because ATGAM is a gamma globulin product, it can be transparent to slightly opalescent, colorless to faintly pink or brown, and may develop a slight granular or flaky deposit during storage. Do not shake ATGAM (diluted or undiluted) because excessive foaming and/or denaturation of the protein may occur.</li>
<li>Dilute ATGAM for intravenous infusion in an inverted bottle of sterile vehicle so the undiluted ATGAM does not contact the air inside. Add the total daily dose of ATGAM to the sterile vehicle <span class="Italics">(see </span><span class="Underline"><a href="#cas">Compatibility and Stability</a></span><span class="Italics">)</span>. Do not exceed a concentration of 4 mg of ATGAM per mL. Gently rotate or swirl the diluted solution to effect thorough mixing.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline">Administration</span></p>
<ul class="Disc"><li>Allow the diluted ATGAM to reach room temperature before infusion. ATGAM is appropriately administered into a vascular shunt, arterial venous <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>, or a high-flow central vein using an in-line filter with a pore size of 0.2 to 1.0 micron. Use the in-line filter with all infusions of ATGAM to prevent the administration of any insoluble material that may develop in the product during storage. Use high-flow veins to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. Do not infuse a dose of ATGAM in less than 4 hours. Always keep appropriate resuscitation equipment at the patient's bedside while ATGAM is being administered. Observe the patient continuously for possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> throughout the infusions <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="cas"></a><a name="section-2.2.3"></a><p></p>
<p class="First"><span class="Underline">Compatibility and Stability</span></p>
<ul class="Disc">
<li>Once diluted, ATGAM has been shown to be physically and chemically stable for up to 24 hours at concentrations of up to 4 mg per mL in the following diluents: 0.9% Sodium Chloride Injection, 5% Dextrose and 0.225% Sodium Chloride Injection, and 5% Dextrose and 0.45% Sodium Chloride Injection.</li>
<li>Do not dilute ATGAM in Dextrose Injection, USP, as low salt concentrations may cause precipitation. Do not use highly acidic infusion solutions since these solutions may contribute to physical instability over time.</li>
<li>Store diluted ATGAM in a refrigerator if it is prepared prior to the time of infusion. Even if it is stored in a refrigerator, do not exceed a total time in dilution of 24 hours (including infusion time).</li>
</ul>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ATGAM 50 mg/mL concentrate for solution for infusion</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Do not administer ATGAM to a patient who has had a systemic reaction (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) during prior administration of ATGAM or any other equine gamma globulin preparation <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Serious immune-mediated reactions have been reported with the use of ATGAM. Clinical signs associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, other infusion associated reactions, and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> have been reported.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Discontinue ATGAM if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occurs. A systemic reaction such as a generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> precludes any additional administration of ATGAM.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Skin Testing</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">To identify those at greatest risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">systemic anaphylaxis</span>, skin testing potential recipients is strongly recommended before commencing treatment. A conservative, conventional approach would first employ epicutaneous (prick) testing with undiluted ATGAM. If the subject does not show a wheal ten minutes after pricking, proceed to intradermal testing with 0.02 mL of a 1:1000 v/v (volume/volume) saline dilution of ATGAM with a separate saline control injection of similar volume. Read the result at 10 minutes: a wheal at the ATGAM site 3 or more mm larger in diameter than that at the saline control site (or a positive prick test) suggests clinical sensitivity and an increased possibility of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> should the drug be dosed intravenously.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The predictive value of this test has not been proven clinically. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred in patients whose skin test is negative. Also, skin testing done as described above will not predict for later development of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>. In the presence of a locally positive skin test to ATGAM, serious consideration to alternative forms of therapy should be given. The risk to benefit ratio must be weighed. If therapy with ATGAM is deemed appropriate following a locally positive skin test, treatment should be administered in a setting where intensive life support facilities are immediately available and a physician familiar with the treatment of potentially life threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> is in attendance.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Transmissible Infectious Agents</h2>
<p class="First">Because ATGAM is made from equine and human blood components, it may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.</p>
<p>No cases of transmission of viral diseases or CJD have been associated with the use of ATGAM.</p>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Pfizer, Inc. at 1-800-438-1985.</p>
<p>Monitor patients for concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Some studies have suggested an increase in the incidence of <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">cytomegalovirus infection</span> in patients receiving ATGAM.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Immunizations</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Do not administer live vaccines to patients about to receive, receiving, or after treatment with ATGAM. Concomitant administration of ATGAM with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with ATGAM treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Hepatic and Renal Function Tests</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and other hematologic abnormalities who have received ATGAM, abnormal tests of liver function (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, alkaline phosphatase) and renal function (serum creatinine) have been observed.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most clinically significant adverse reactions are <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and abnormal renal and liver function tests.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of ATGAM has been evaluated in 367 patients with renal transplant and 109 patients with <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>.</p>
<p>The renal transplantation and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below.</p>
<p>The most commonly reported adverse reactions (occurring in greater than 10% of patients) are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</p>
<a name="table1"></a><table width="65%">
<caption><span>Table 1. Adverse Reactions Occurring in ≥1% of Patients who Received ATGAM</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">Adverse Reaction<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Rrule" align="center">ATGAM</th>
</tr>
<tr>
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Frequency (%)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">(N = 476)</th>
</tr>
</thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Percentages are treatment-emergent all-causality events</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">39.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Rrule" align="center">26.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">25.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">21.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">17.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">17.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Rrule" align="center">9.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">5.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">4.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">4.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">3.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">3.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span></td>
<td class="Rrule" align="center">3.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">2.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Rrule" align="center">2.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">2.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">2.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></td>
<td class="Rrule" align="center">1.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4125011" conceptname="Arteriovenous fistula thrombosis">Arteriovenous fistula thrombosis</span></td>
<td class="Rrule" align="center">1.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function test abnormal</span></td>
<td class="Rrule" align="center">1.0</td>
</tr>
</tbody>
</table>
<a name="table2"></a><table width="65%">
<caption><span>Table 2. Adverse Reactions Occurring in &lt;1% of Patients who Received ATGAM </span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">Adverse Reaction<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</th>
<th class="Rrule" align="center">ATGAM</th>
</tr>
<tr>
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Frequency (%)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">(N = 476)</th>
</tr>
</thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Percentages are treatment-emergent all-causality events</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437992" conceptname="Renal function tests abnormal">Renal function test abnormal</span></td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Herpes simplex</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">Wound dehiscence</span></td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Encephalitis</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316367" conceptname="Thrombosis of renal artery">Renal artery thrombosis</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Iliac vein occlusion</td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngospasm</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">Dermatitis allergic</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">Periorbital edema</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span></td>
<td class="Rrule" align="center">0.2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of ATGAM. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>: <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">Hepatitis viral</span>, <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">Localized infection</span>, Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p>
<p><span class="Italics">Blood and lymphatic system disorders</span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span></p>
<p><span class="Italics">Psychiatric disorders</span>: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac failure congestive</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">Oral pain</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">Flank pain</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p>
<p><span class="Italics">Renal and urinary disorders</span>: <span class="product-label-link" type="condition" conceptid="4104152" conceptname="Large kidney">Kidney enlargement</span>, <span class="product-label-link" type="condition" conceptid="4134923" conceptname="Rupture of renal pelvis">Kidney rupture</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Renal failure acute</span></p>
<p><span class="Italics">Congenital, familial and genetic disorders</span>: <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">Aplasia</span></p>
<p><span class="Italics">General disorders and administration site conditions</span>: Infusion site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, Infusion site <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Previously masked reactions to ATGAM may appear when the dose of corticosteroids and other immunosuppressants is being reduced.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">ATGAM was not teratogenic in rats or monkeys at a dose up to 20 mg/kg. However, 20 mg/kg/day ATGAM for 16 days during organogenesis in cynomolgus monkeys was fetotoxic. No fetal or maternal toxicity was seen with 10 mg/kg/day ATGAM administered for 16 days during organogenesis <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
<p>There are no adequate and well-controlled studies in pregnant women. It is also not known whether ATGAM can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.</p>
<p>ATGAM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">In animal studies, a single dose of ATGAM up to 40 mg/kg was not detected at the limit of quantification in the milk of lactating cynomolgus monkeys. It is not known whether ATGAM is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing neonates and infants from ATGAM, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Experience with children has been limited. ATGAM has been administered safely to a small number of pediatric renal allograft recipients and pediatric <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> patients at dosage levels comparable to those in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical experience in a limited number of elderly patients (≥65 years of age) has not identified differences in responses between the elderly and younger patients. The dose for an elderly patient should be selected with caution, starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in this age group.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The maximum tolerated dose of ATGAM Sterile Solution would be expected to vary from patient to patient due to the biological nature of the product. The largest single daily dose known to be administered to a patient (renal transplant recipient) was 7,000 mg administered at a concentration of approximately 10 mg/mL Sodium Chloride Injection, USP, seven times the recommended total dose and infusion concentration. In this patient, the administration of ATGAM was not associated with any signs of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> or late sequelae.</p>
<p>A maximum therapeutic dose has not been established therefore the definition of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> for ATGAM has not been clearly defined. Some renal transplant patients have received up to 50 doses in 4 months, and others have received 28-day courses of 21 doses followed by as many as 3 more courses for the treatment of acute rejection. The incidence of toxicologic manifestations did not increase with any of these regimens; however, close monitoring of the patient is recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ATGAM Sterile Solution contains lymphocyte immune globulin, anti-thymocyte globulin [equine]. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. ATGAM is a transparent to slightly opalescent aqueous protein solution. It may appear colorless to faintly pink or brown and is nearly odorless. It may develop a slight granular or flaky deposit during storage <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</p>
<p>Precise methods of determining the potency of ATGAM have not been established, thus activity may potentially vary from lot to lot. Before release for clinical use, each lot of ATGAM is tested to assure its ability to inhibit rosette formation between human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and sheep red blood cells <span class="Italics">in vitro</span>. In each lot, antibody activity against human red blood cells and platelets is also measured and determined to be within acceptable limits. Only lots that meet the acceptance criteria for pyrogens and test negative for antihuman serum protein antibody and antiglomerular basement membrane antibody are released.</p>
<p>Each milliliter of ATGAM contains 50 mg of horse gamma globulin stabilized in 0.3 molar glycine to a pH of approximately 6.8.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ATGAM is composed of antibodies that bind a wide variety of proteins on the surface of <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. In addition, ATGAM binds to granulocytes, platelets, bone marrow cells, and other cell types. The mechanism of ATGAM-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> has not been determined. Published data indicate that the primary mechanism is the depletion of circulating <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, with greatest effect on T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Lymphocyte depletion may be caused by complement dependent lysis and/or activation-induced <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>. In addition, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may be mediated by the binding of antibodies to <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> which results in partial activation and induction of T lymphocyte anergy.</p>
<p>The mechanism of ATGAM therapy for <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> is attributed to its immunosuppressive actions. In addition, ATGAM directly stimulates the growth of hematopoietic stem cells and release of hematopoietic growth factors such as interleukin-3 and granulocyte/macrophage colony stimulating factor.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>During infusion of 10 to 15 mg/kg/day, the mean peak value (n = 27 renal transplant patients) was found to be 727 ± 310 μg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span></p>
<p>The half-life of equine immunoglobulin after ATGAM infusion was found to be 5.7 ± 3.0 days in one group of recipients. The range for half-life was 1.5 to 13 days.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Mutagenicity and carcinogenicity studies have not been conducted on ATGAM.</p>
<p>In fertility studies, ATGAM at doses 10, 20 and 40 mg/kg/day was administered to cynomolgus monkeys (Macaca fascicularis) for 14 days either before (male monkeys) or before and after (female monkeys) cohabitation with untreated mates. ATGAM treatment was not associated with male or female hormonal or copulation behavior changes. A decrease in fertility index in female monkeys receiving ATGAM was seen. Female toxicity, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, was observed with ATGAM doses of ≥20 mg/kg/day. While the etiology of this toxicity is uncertain, it may be attributed to <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> due to cross-reactivity of ATGAM to a monkey red blood antigen.</p>
<p>In embryo-fetal toxicity studies, ATGAM was administered to rats and cynomolgus monkeys for 11 and 16 days, respectively during organogenesis. In rats, hypoplastic cervical vertebrae, a finding consistent with delayed skeletal development, were observed in fetuses whose dams received ATGAM at doses of 100 mg/kg/day during organogenesis. In monkey reproduction studies, maternal toxicity (<span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, decreased body weight and loss of appetite) was observed with ATGAM doses ≥20 mg/kg/day after 16 days of dosing. <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal deaths</span> occurred in dams treated with 20 mg/kg/day ATGAM earlier in organogenesis (days 20–35), but not when treatment was given at a later part of organogenesis (days 35–50). The maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> were attributed to maternal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to red blood cell antigen that humans do not share. Therefore, this toxicity is not considered relevant to human fetal development.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Renal Allograft Rejection</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Renal <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Transplant Rejection</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1.1"></a><p></p>
<p class="First"><span class="Italics">US Studies</span></p>
<p>The effectiveness of ATGAM for treatment of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span> was evaluated in three different treatment applications: as a substitute for standard therapy, in conjunction with standard therapy at the time of diagnosis of the first rejection episode, and in conjunction with standard therapy in steroid resistant rejection episodes.</p>
<p>A randomized controlled trial of the use of ATGAM as a substitute for standard therapy for treatment of the first acute rejection episode was conducted at one transplant center in recipients of living related renal allografts. A total of 22 patients were studied; 11 in each of the two treatment groups [ATGAM versus standard therapy (bolus doses of Solu-Medrol<span class="Sup">®</span>)]. Patients randomized to the ATGAM group received 14–21 doses of ATGAM therapy, starting on the day the rejection was diagnosed. ATGAM was administered daily according to a dose-by-rosette regimen which resulted in a mean daily dose of approximately 15 mg/kg. Patients randomized to the control group received Solu-Medrol<span class="Sup">®</span> at a dosage of 15 mg/kg starting on the day the rejection was diagnosed, administered either daily or on alternate days for 3 to 7 doses to complete a maximum total dose of 5,000 mg for the course of the rejection episode. In this study, ATGAM was at least effective as standard therapy for treatment of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span>. All 11 ATGAM treated patients achieved resolution of first rejection compared with 10/11 control patients. At one year, the functional graft survival rate was 91% in the ATGAM group (10/11) and 64% in the control group (7/11). Patient survival was similar in the two treatment groups (11/11 ATGAM patients versus 10/11 control patients).</p>
<p>The effect of ATGAM when administered in conjunction with standard therapy at the time of diagnosis of the first rejection episode was studied under two different protocols with cadaveric and living related renal transplant patients. The results from these studies demonstrate the efficacy associated with the addition of ATGAM to standard therapy for treatment of the first rejection episode in renal allograft recipients. In Study 1, a randomized controlled, two center trial of ATGAM use for treatment of acute rejection in cadaveric renal transplant patients, the addition of ATGAM to standard rejection therapy (methylprednisolone sodium succinate) resulted in an increased frequency of resolution of the first acute rejection episode which was statistically significant (p &lt;0.01). ATGAM-treated patients achieved a rejection resolution rate of 80% (36/45) compared with 54% (25/46) in the control group. There was a statistically significant improvement in functional graft survival favoring the ATGAM group (p &lt;0.01), and a statistically significant steroid sparing effect during the first rejection episode among patients in the ATGAM group. There was no difference in the patient survival rate between the two treatment groups. Study 2 was a randomized controlled trial conducted at five different transplant centers. In this study, the addition of ATGAM to standard rejection therapy (bolus doses of Solu-Medrol<span class="Sup">®</span>) for treatment of acute rejection in recipients of living related renal transplants resulted in an increased frequency of rejection resolution and improvement in functional graft survival. Due to the small sample size, the difference between the ATGAM group and the control group in functional graft survival rate did not achieve statistical significance. Marginal statistical significance was demonstrated in rejection reversal rate and intravenous steroid sparing among ATGAM patients (p=0.10 and p=0.07). Patient survival rates were similar in the two treatment groups.</p>
<p>Results from randomized controlled trials in patients with first acute renal allograft rejection episodes refractory to conventional steroid therapy have demonstrated that ATGAM, when administered in conjunction with standard therapy, yields efficacy results superior to those of standard therapy alone. One study investigated two different regimens of ATGAM; immediate and delayed therapy. Patients were enrolled at the time of first rejection episode and randomized among three treatment groups: control (no ATGAM), immediate ATGAM, and delayed ATGAM. Patients in all three treatment groups received standard rejection therapy in the form of bolus doses of Solu-Medrol<span class="Sup">®</span> 15 mg/kg/day IV, while patients in the two ATGAM groups received ATGAM therapy in addition to Solu-Medrol<span class="Sup">®</span>. In the immediate ATGAM group, ATGAM administration started at the time of diagnosis of rejection (concurrent with standard therapy). In the delayed ATGAM group, ATGAM administration started on rejection day 4 (following the first three doses of Solu-Medrol<span class="Sup">®</span>). Patients in both of the treated groups received from 10 to 21 doses of ATGAM. Results favored the two ATGAM groups (and particularly the immediate ATGAM group) in both outcome of first rejection and functional graft survival. The improvement in functional graft survival was statistically significant (p=0.05). There was also a statistically significant difference in patient survival rate favoring the ATGAM-treated groups (p=0.02). </p>
<p>The effectiveness of ATGAM for reversal of acute renal allograft rejection was also demonstrated in other controlled studies performed in various medical centers. In these studies, ATGAM was administered at time of diagnosis of the first rejection episode at a range of 10 to 15 mg/kg per day for 14 to 15 days, followed by alternate day therapy for a total of 21 doses in 28 days.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	<span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></h2>
<p class="First">The use of ATGAM for the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> in patients who are unsuitable for bone marrow transplantation is based on data from three controlled studies.</p>
<p>The effectiveness of the ATGAM therapy in the studies described below was evaluated by the hematological response and survival rates (Table 3).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">10 to 20 mg/kg daily for 8 to 14 days</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1.1"></a><p></p>
<p class="First"><span class="Italics">Study 1</span></p>
<p>A total of 41 patients with moderate or severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> ages 6 to 69 years, who were not candidates for bone marrow transplantation were enrolled in a randomized controlled study. The objective of this study was to determine the efficacy of ATGAM as a single agent, in restoring hematopoiesis in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>. Twenty-one (n=21) patients in the ATGAM treatment group received 20 mg/kg/day for 8 days, while control patients (n=20) were observed for 3 months. All patients were given oral prednisone (40 mg/m<span class="Sup">2</span>/day) starting on day 8 then tapered over 1 to 2 weeks.</p>
<p>At 3 months post-study enrollment, 11 patients in the supportive care group who showed no improvement became eligible and were crossed over to receive ATGAM therapy. Efficacy was evaluated as sustained improvement in peripheral blood counts within 3 months of entry into the study. A statistically significant (p&lt;0.01) difference was observed between the two treatment groups in hematological improvement based on the investigator's evaluation; 11 of 21 (52%) patients in the ATGAM group responded, compared with no patients (0 of 20) in the control group. Six of the 11 crossover patients from the control group showed improvement after 3 months of therapy. Overall, of 32 patients in both the ATGAM group and the control group who crossed over to receive ATGAM, 17 patients (53%) had a hematological improvement. Estimated 1-year survival rate was 62% for all 32 patients treated with ATGAM. The 2-year survival rate was 100% among the ATGAM responders [17 of the 32 patients (53%) compared to 14% for the nonresponders].</p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and erythematous or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticarial rash</span> were seen in all ATGAM treated patients. Platelet counts decreased during ATGAM infusion and daily platelet transfusions were necessary. <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span> occurred in all patients within 6 to 18 days of ATGAM initiation and was well-controlled with standard therapy. Three patients experienced transient <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1.2"></a><p></p>
<p class="First"><span class="Italics">Study 2</span></p>
<p>A randomized double-blind, placebo prospective, controlled study was conducted to compare the safety and efficacy of ATGAM and androgen (oxymetholone; OXY) immunosuppressive therapy with the combination of ATGAM, androgen (OXY) and an infusion of HLA mismatched bone marrow in patients with severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> who were not candidates for bone marrow transplantation. Allocation to treatment group was based on the availability of mismatched bone marrow donors. A total of 42 patients, ages 1 to 69 years were treated. Eighteen patients received ATGAM at a dose of 16 mg/kg/day for 10 doses with concomitant <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> (OXY) at a dose of 3 mg/kg/day for a minimum of 3 months, and 24 patients received an infusion of bone marrow from an HLA-mismatched donor 48 hours after the completion of ATGAM treatment.</p>
<p>At 3 months after entry into the study, 51% of patients with disease of idiopathic etiology (21 of the 41 evaluable patients from both groups) showed improvement based on investigator's evaluation of transfusion requirements and peripheral blood counts. Hematological response rate (complete/moderate based on sponsor's evaluation) at 3 months for the ATGAM and androgen group was 44% compared with 43% for the group receiving ATGAM, androgen and bone marrow infusion. The group of patients who received mismatched bone marrow infusion had better estimated 1-year survival rate, although the difference between these estimates was not statistically significant (p=0.14); 83% at 12 months for the group receiving bone marrow infusion versus 59% for the ATGAM and androgen alone group. Estimated 1-year survival rate for both groups combined was 73%.</p>
<p>The most commonly reported adverse events were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>A pooled analysis of data from Studies 1 and 2 revealed an overall estimated 1-year survival rate of 69% in ATGAM-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1.3"></a><p></p>
<p class="First"><span class="Italics">Study 3</span></p>
<p>A total of 53 patients (3 to 76 years of age) participated in this randomized, placebo-controlled, double-blind study to determine if <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> add to the efficacy of ATGAM in providing favorable hematologic response rates in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>. All patients were treated with ATGAM 20 mg/kg/day IV for 8 days, and were randomized to receive the oral androgen (oxymetholone 4 mg/kg/day or fluoxymesterone 25 mg/m<span class="Sup">2</span>/day) (n=26), or a matched placebo (n=27). Both groups received oral prednisone (40 mg/m<span class="Sup">2</span>/day) beginning on Day 8 which was tapered and discontinued in 1 to 2 weeks. A group of historical controls from previous studies (n=68; 1 to 72 years of age) who received ATGAM (20 mg/kg/day IV for 8 days) without <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> were included for treatment results comparison. The proportions of subjects who presented complete or partial response at 6 months were 42% in the ATGAM plus androgen group, 44% in the ATGAM plus placebo group, and 51% in the historical controls. The difference in response rates was not significant (p&gt;0.9). Survival at 2 years was also comparable in the two groups for patients with severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>; 55% in the ATGAM plus androgen group compared with 50% in the ATGAM plus placebo group (p=0.65), and 56% for the historical controls. In patients with moderate <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, two-year survival for the ATGAM plus androgen group was 63% compared with 100% in those receiving ATGAM plus placebo and 72% in the historical controls who received ATGAM alone.</p>
<p>Adverse reactions in both groups were comparable and included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> during ATGAM infusion, as well as symptoms of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> in all patients. Five patients had asymptomatic <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; six patients required antihypertensive therapy. Alanine transaminase or alkaline phosphatase levels increased to &gt;2 times the upper limits of normal in 7 patients receiving ATGAM plus androgen, and in nine patients receiving ATGAM plus placebo.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3. Key Studies with ATGAM for the Treatment of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic Anemia</span></span></caption>
<col align="left" valign="middle" width="15%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="10%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Study</th>
<th class="Rrule" align="center">ATGAM + comparator or other therapy</th>
<th class="Rrule" align="center">No. of Subjects</th>
<th class="Rrule" align="center">Response rate %<br>(endpoint)<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th class="Rrule" align="center">P Value</th>
<th class="Rrule" align="center">Survival rate %<br>(time point)</th>
<th class="Rrule" align="center">P Value (or 95% CI)</th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Hematologic response was defined differently in different studies.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Sponsor's evaluation of response</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Investigator's evaluation of response</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd>This survival estimate includes the 21 subjects who were randomized to receive ATGAM, plus another 11 subjects who were crossed over from the control group.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">¶</a></dt>
<dd>Patients with severe <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> only.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">10 to 20 mg/kg/day for 8 to 14 days</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Study 1</td>
<td class="Rrule" align="center">ATGAM</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">47<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>/ 52<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a> (3 mo)</td>
<td class="Rrule" align="center" rowspan="2">&lt;0.01<a href="#footnote-6" class="Sup">†</a>/&lt;0.01<a href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" rowspan="2">62<a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a> (12 mo)</td>
<td class="Rrule" align="center" rowspan="2">NA</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">Control</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">6<a href="#footnote-6" class="Sup">†</a>/ 0<a href="#footnote-7" class="Sup">‡</a> (3 mo)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Study 2</td>
<td class="Rrule" align="center">ATGAM + Bone marrow infusion</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">43 (3 mo)</td>
<td class="Rrule" align="center" rowspan="2">Not reported</td>
<td class="Rrule" align="center">83 (12 mo)</td>
<td class="Rrule" align="center" rowspan="2">=0.14</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">ATGAM</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">44 (3 mo)</td>
<td class="Rrule" align="center">59 (12 mo)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3">Study 3</td>
<td class="Rrule" align="center">ATGAM + Androgen</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">42 (6 mo)</td>
<td class="Rrule" align="center" rowspan="2">&gt;0.9</td>
<td class="Rrule" align="center">55<a name="footnote-reference-9" href="#footnote-9" class="Sup">¶</a> (24 mo)</td>
<td class="Rrule" align="center" rowspan="2">=0.65</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">ATGAM + Placebo</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">44 (6 mo)</td>
<td class="Rrule" align="center">50<a href="#footnote-9" class="Sup">¶</a> (24 mo)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">ATGAM historical controls</td>
<td class="Rrule" align="center">68</td>
<td class="Rrule" align="center">51 (6 mo)</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">56 (24 mo)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Hardy MA, Nowygrod R, Elberg A, Appel G. Use of ATG in treatment of steroid-resistant rejection. Transplantation 1980; 29(2):162–4.</li>
<li>Nowygrod R, Appel G, Hardy MA. Use of ATG for reversal of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span>. Transplant Proc 1981; 13(1):469–72.</li>
<li>Filo RS, Smith EJ, Leapman SB. Reversal of acute renal allograft rejection with adjunctive ATG therapy. Transplant Proc 1981; 13(1):482–90.</li>
<li>Shield CF III, Cosimi AB, Tolkoff Rubin N, et al. Use of antithymocyte globulin for reversal of <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">acute allograft rejection</span>. Transplantation 1979; 28(6):461–4.</li>
<li>Rubin RH, Cosimi AB, Hirsch MS, Herrin JT. Effects of antithymocyte globulin on <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">cytomegalovirus infection</span> in renal transplant recipients. Transplantation 1981; 31(2):143–5.</li>
<li>Cosimi AB, Wortis HH, Delmonico FL, Russell PS. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery 1976; 80(2):155–63.</li>
<li>Wechter WJ, Brodie JA, Morrell RM, et al. Antithymocyte globulin (ATGAM) in renal allograft recipients: multicenter trials using a 14-dose regimen. Transplantation 1979; 28(4):294–302.</li>
<li>Butt KMH, Zielinski CM, Parsa I, et al. Trends in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> for kidney transplantation. Kidney Int 1978; 13(Suppl 8): S95–S8.</li>
<li>Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadaveric renal transplant outcome in children. Pediatric Nephrol 1991; 5:137–42.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ATGAM Sterile Solution, containing 50 mg/mL lymphocyte immune globulin, anti-thymocyte globulin [equine], is supplied as follows:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left">5 – 5 mL ampoules</td>
<td align="right">NDC 0009-7224-02</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store in a refrigerator at 2° to 8°C (36° to 46°F). DO NOT FREEZE.</p>
<p>For storage conditions of diluted solution, see <span class="Italics"><a href="#S2.2">Dosage and Administration (2.2)</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients receiving ATGAM that they will be monitored in a facility equipped and staffed with adequate laboratory and supportive medical resources.</p>
<p>Inform patients that ATGAM may cause serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or abnormal liver or renal function.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Underline">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<ul class="Disc"><li>Advise the patient to discontinue ATGAM and seek immediate medical attention if any signs/symptoms of an allergic or immune reaction occur <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<p class="First"><span class="Underline">Skin Testing</span></p>
<ul class="Disc"><li>Despite screening and testing, products manufactured using components of human blood such as ATGAM may carry a risk of transmitting infectious agents (e.g., viruses). Discuss the risks and benefits of therapy with patients before initiating treatment <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<ul class="Disc"><li>Advise the patient to discontinue ATGAM and report any sign/symptoms of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>) <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S5.2">(5.2)</a>, <a href="#S6">(6)</a>]</span>.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Healthcare providers should refer to labels.fda.gov or DailyMed for the most updated version of the labeling.</p>
<p>This product's label may have been updated. For full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd545ba1-2366-4df1-bd67-10dfd7632b54&amp;name=atgam-01.jpg"></p>
<p>U.S. Govt. License No. 1216</p>
<p>LAB-0019-7.0</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Ampule Label</h1>
<p class="First"><span class="Bold">5 mL</span></p>
<p>NDC 0009-7224-01</p>
<p><span class="Bold">Atgam<span class="Sup">®</span></span></p>
<p>lymphocyte immune globulin,<br>anti-thymocyte globulin (equine)</p>
<p><span class="Bold">250 mg protein</span></p>
<p><span class="Bold">50 mg/mL</span><br>For I.V. use only</p>
<p><span class="Bold">DOSAGE AND USE:</span> See accompanying prescribing<br>information. U.S. License No. 1216.</p>
<p><span class="Bold">ATTENTION—May contain particles; this is<br>normal. Use 0.2µ to 1.0µ in-line filter. See insert.</span></p>
<p>Distributed by Pharmacia &amp; Upjohn Co<br>Division of Pfizer Inc, NY, NY 10017</p>
<p><span class="Bold">Rx only</span></p>
<p>PAA042882</p>
<p>LOT / EXP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mL Ampule Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd545ba1-2366-4df1-bd67-10dfd7632b54&amp;name=atgam-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5–5 mL Ampule Carton</h1>
<p class="First">NDC 0009-7224-02<br>Contains 5 of NDC 0009-7224-01</p>
<p><span class="Bold">5–5 mL Ampoules<br>(single use containers)</span></p>
<p><span class="Bold">Atgam<span class="Sup">®</span></span></p>
<p>lymphocyte immune globulin,<br>anti-thymocyte globulin (equine)<br><span class="Bold">250 mg protein<br>50 mg/mL</span></p>
<p><span class="Bold">ATTENTION — This product may contain a granular<br>or flaky deposit; this is normal. See infusion<br>instructions described in the enclosed product<br>insert.</span></p>
<p><span class="Bold">For I.V. use only</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 5–5 mL Ampule Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd545ba1-2366-4df1-bd67-10dfd7632b54&amp;name=atgam-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATGAM 		
					</strong><br><span class="contentTableReg">equine thymocyte immune globulin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-7224</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EQUINE THYMOCYTE IMMUNE GLOBULIN</strong> (EQUINE THYMOCYTE IMMUNE GLOBULIN) </td>
<td class="formItem">EQUINE THYMOCYTE IMMUNE GLOBULIN</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-7224-02</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-7224-01</td>
<td class="formItem">5 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103676</td>
<td class="formItem">11/17/1981</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0009-7224), API MANUFACTURE(0009-7224), LABEL(0009-7224), MANUFACTURE(0009-7224), PACK(0009-7224)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>caf0640d-ca20-4dc8-b0b6-29d80bc75ee7</div>
<div>Set id: bd545ba1-2366-4df1-bd67-10dfd7632b54</div>
<div>Version: 9</div>
<div>Effective Time: 20150413</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
